Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Schöffski, Patrick [VerfasserIn]   i
 Ray-Coquard, Isabelle Laure [VerfasserIn]   i
 Cioffi, Angela [VerfasserIn]   i
 Bui, Nguyen Bin [VerfasserIn]   i
 Bauer, Sebastian [VerfasserIn]   i
 Hartmann, Joerg Thomas [VerfasserIn]   i
 Krarup-Hansen, Anders [VerfasserIn]   i
 Grünwald, Viktor [VerfasserIn]   i
 Sciot, Raf [VerfasserIn]   i
 Dumez, Herlinde [VerfasserIn]   i
 Blay, Jean-Yves [VerfasserIn]   i
 Le Cesne, Axel [VerfasserIn]   i
 Wanders, Jantien [VerfasserIn]   i
 Hayward, Carolyn [VerfasserIn]   i
 Marreaud, Sandrine [VerfasserIn]   i
 Ouali, Monia [VerfasserIn]   i
 Hohenberger, Peter [VerfasserIn]   i
Titel:Activity of eribulin mesylate in patients with soft-tissue sarcoma
Titelzusatz:a phase 2 study in four independent histological subtypes
Verf.angabe:Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, Nguyen Bin Bui, Sebastian Bauer, Joerg Thomas Hartmann, Anders Krarup-Hansen, Viktor Grünwald, Raf Sciot, Herlinde Dumez, Jean-Yves Blay, Axel Le Cesne, Jantien Wanders, Carolyn Hayward, Sandrine Marreaud, Monia Ouali, Peter Hohenberger, for the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)
E-Jahr:2011
Jahr:[October 2011]
Umfang:8 S.
Illustrationen:Diagramme
Fussnoten:Gesehen am 25.10.2022
Titel Quelle:Enthalten in: The lancet. Oncology
Ort Quelle:London : The Lancet Publ. Group, 2000
Jahr Quelle:2011
Band/Heft Quelle:12(2011), 11, Seite 1045-1052
ISSN Quelle:1474-5488
Abstract:Background - Eribulin inhibits microtubule dynamics via a mechanism distinct from that of other tubulin-targeting drugs, inducing cell-cycle arrest and tumour regression in preclinical models. We assessed the activity and safety of eribulin in four strata of patients with different types of soft-tissue sarcoma. - Methods - In this non-randomised multicentre phase 2 study, patients were included if they had progressive or high-grade soft-tissue sarcoma and had received no more than one previous combination chemotherapy or up to two single drugs for advanced disease. They were stratified by the type of soft-tissue sarcoma they had. Eribulin was given intravenously at a concentration of 1·4 mg/m2 over 2-5 min at days 1 and 8 every 3 weeks to primarily assess progression-free survival at 12 weeks (RECIST 1.0), which we evaluated in all patients who started treatment. Safety analyses were done in all patients who started treatment. This trial is registered at ClinicalTrials.gov, number NCT00413192. - Findings - Of 128 patients included, 37 had adipocytic sarcoma, 40 had leiomyosarcoma, 19 had synovial sarcoma, and 32 had other sarcomas. 12 (31·6%) of 38 patients with leiomyosarcoma evaluable for the primary endpoint, 15 (46·9%) of 32 patients with adipocytic sarcoma, four (21·1%) of 19 with synovial sarcoma, and five (19·2%) of 26 in other sarcomas were progression-free at 12 weeks. The most common grade 3-4 adverse events were neutropenia (66 [52%] of 127 patients evaluable for safety), leucopenia (44 [35%]), anaemia (nine [7%]), fatigue (nine [7%]), febrile neutropenia (eight [6%]), abnormal alanine aminotransferase concentrations (six [5%]), mucositis (four [3%]), and sensory neuropathy (four [3%]). - Interpretation - Eribulin deserves further study in this setting, based on progression-free survival at 12 weeks in leiomyosarcoma and adipocytic sarcoma. - Funding - Eisai Limited, Hatfield, UK.
DOI:doi:10.1016/S1470-2045(11)70230-3
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/S1470-2045(11)70230-3
 Volltext: https://www.sciencedirect.com/science/article/pii/S1470204511702303
 DOI: https://doi.org/10.1016/S1470-2045(11)70230-3
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1819861139
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68978029   QR-Code
zum Seitenanfang